- Home
- HSII vs COGT Comparison
HSII vs COGT Comparison
Compare HSII & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- COGT
- Stock Information
- Founded
- HSII 1953
- COGT 2014
- Country
- HSII United States
- COGT United States
- Employees
- HSII N/A
- COGT N/A
- Industry
- HSII Diversified Commercial Services
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- HSII Consumer Discretionary
- COGT Health Care
- Exchange
- HSII Nasdaq
- COGT Nasdaq
- Market Cap
- HSII 904.3M
- COGT 895.8M
- IPO Year
- HSII 1999
- COGT 2018
- Fundamental
- Price
- HSII $46.09
- COGT $8.03
- Analyst Decision
- HSII Buy
- COGT Buy
- Analyst Count
- HSII 2
- COGT 6
- Target Price
- HSII $46.00
- COGT $14.17
- AVG Volume (30 Days)
- HSII 156.8K
- COGT 1.5M
- Earning Date
- HSII 02-24-2025
- COGT 02-24-2025
- Dividend Yield
- HSII 1.30%
- COGT N/A
- EPS Growth
- HSII N/A
- COGT N/A
- EPS
- HSII 1.83
- COGT N/A
- Revenue
- HSII $1,075,544,000.00
- COGT N/A
- Revenue This Year
- HSII $7.90
- COGT N/A
- Revenue Next Year
- HSII $3.07
- COGT N/A
- P/E Ratio
- HSII $25.23
- COGT N/A
- Revenue Growth
- HSII 6.55
- COGT N/A
- 52 Week Low
- HSII $27.07
- COGT $4.28
- 52 Week High
- HSII $49.02
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- HSII 62.14
- COGT 46.50
- Support Level
- HSII $45.67
- COGT $6.60
- Resistance Level
- HSII $46.48
- COGT $8.72
- Average True Range (ATR)
- HSII 0.98
- COGT 0.51
- MACD
- HSII 0.22
- COGT 0.09
- Stochastic Oscillator
- HSII 89.20
- COGT 67.45
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments includes the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.